1. Curriculum vitae

BIOGRAPHICAL SKETCH	
Name: Weber, Martin, MD	*Position/Title:* Associate Professor ("W2"), Senior physician ("Oberarzt"); Department of Neuropathology, Department of Neurology, University of Göttingen

Education

Institution and Location	Degree	Year	Field of Study
Medical School of the University of Regensburg, Germany	Preclinical examination, "Physikum"	1997	Medicine
Medical School of the University of Würzburg, Germany	Clinical examination, "Staatsexamen"	2001	Medicine
Medical School of the University of Würzburg, Germany	MD thesis, "Dr. med." *magna cum laude*	2003	Medicine
Residency in Neurology at the Ludwig-Maximilians University and the Technische Universität München, Munich, Germany	Board certification in neurology	2011	Neurology
Department of Neurology, Technische Universität München, Munich, Germany	Habilitation/ Professorial qualification	2011	Neurology
Faculty appointment at the University of Göttingen, Germany	Associate professor, "W2", tenure track	2013	Translational Neuro-inflammation

Research and Professional Experience

Employment

2002-2004 **Residency in Neurology, Postdoctoral-fellowship** Institute of Clinical Neuroimmunology (Prof. Dr. R. Hohlfeld) and Department of Neurology (Prof. Dr. Th. Brandt) Ludwig-Maximilians University, Munich-Großhadern; Max-Planck-Institute for Neurobiology (Prof. Dr. H. Wekerle), Germany

2004-2007 **Postdoctoral-fellowship** at the University of California, San Francisco, USA; Department of Neurology (Prof. Dr. S. Hauser), Laboratory of Prof. Dr. S. Zamvil

2008-02/2011 **Senior Scientist, Residency in Neurology,** Department of Neurology (Prof. Dr. B. Hemmer), Technische Universität München, Munich, Germany

03/2011- **Reasearch group leader and board-certified Neurologist**, since 10/2012

09/2012 **Habilitation (professorial qualification) and *Venia legendi* for Neurology**, Department of Neurology, Technische Universität München, Munich, Germany

since 10/2012 **Research group leader** at the Department of Neuropathology (Prof. Dr. W. Brück), **Senior physician** ("Oberarzt") at the Department of Neurology (Prof. Dr. M. Bähr), University of Göttingen, Germany

since 04/2013 **Head of the MS outpatient center**, University of Göttingen, Germany

since 07/2013 **Associate Professor** ("W2") for Translational Neuroinflammation, tenure track, University of Göttingen, Germany

since 09/2016 **Deputy head** of the **Laboratory for neurochemical analyses** (including cerebrospinal fluid diagnostic), University of Göttingen, Germany

Professional memberships and other experience

Memberships:	International Society of Neuroimmunology (ISNI, since 2004), American Academy of Neurology (AAN, since 2005), European Neurological Society (ENS, since 2007), European Comitte for Treatment and Research in Multiple Sclerosis (ECTRIMS, since 2007), German Neurological Society (DGN, since 2008), Medical Advisory Board of the German Multiple Sclerosis Society (DMSG; since 2014), German Competence Network Multiple Sclerosis (KKNMS; since 2015), Neuromyelitis Optica study group (NEMOS; since 2015)
Manuscript Reviewer:	Nature Medicine, Nature Immunology, Journal of Experimental Medicine, Proceedings of the National Academy of Science (PNAS), GLIA, Annals of Neurology, Acta Neuropathologica, Journal of Neuroimmunology, Journal of Neurology, European Journal of Neurology, European Journal of Immunology, Journal of Neuroinflammation, Therapeutic advances in Neurological Disorders, Multiple Sclerosis Journal, PloS ONE, Annals of Clinical and Experimental Neurology, Neurology Neuroimmunology and Neuroinflammation
Academic Editor	PLoS ONE
Grant Reviewer	Swiss MS Society, Swiss National Science Foundation, Neurological Foundation of New Zealand, Israel Science Foundation

Honors

2003	Junior-scientist award at the 13th meeting of the European Neurological Society (ENS)
2004	Fellowship of the Deutsche Forschungsgemeinschaft (DFG)
2006	Fellowship of the US National Multiple Sclerosis Society (NMSS)
2007	Scholarship award of the Keystone meeting "The Macrophage: Homeostasis, Immunoregulation and Disease"
2007	Fellowship Award of the American Neurological Association (ANA)
2011	Pilot award of the NMSS: "Does anti-CD20 treatment abrogate B cell regulation in multiple sclerosis?"
2011	Junior scientist award of the Roman, Marga und Mareille Sobek-Stiftung for Multiple Sclerosis Research
2012	Election to the Pro Futura Programm of the University of Göttingen

2. Ten most significant publications

1. **Weber M.S.,** Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. *Brain.* 2004 Jun;127(Pt 6):1370-8.
2. Stüve* O., Youssef* S., **Weber* M.S**., Nessler S., von Büdingen H.-C., Hemmer B., Steinman+ L. and Zamvil+ S.S.. Immunomodulatory synergy by combination of glatiramer acetate and atorvastatin in treatment of CNS autoimmunity (***Co-first authors**, +Co-last authors). *J Clin Invest* 2006 Mar;116(4):1037-1044.
3. Dunn S.E., Youssef S., Goldstein M.J., Prod'homme T., **Weber M.S.,** Zamvil S.S., and Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a

mechanism of modulation of autoimmunity by atorvastatin. *J Exp Med.* 2006 Feb;203(2):401-12. 13

4. **Weber M.S.**, Prod´homme T., Youssef S., Rundle C.D., Dunn S.E.., Lee L. Patarroyo J.C., Stüve O., Sobel R.A., Steinman L. and Zamvil S.S. Type II monocytes modulate T cell-mediated autoimmunity *Nat Med*. 2007 Aug;13(8):935-43.
5. **Weber M.S.**, Prod´homme T., Patarroyo J.C., Karnezis T., Molnarfi N., Karnezis T., Lehmann-Horn K., Danilenko D.M., Eastham-Anderson J., Slavin A., Linington C., Bernard C.C.A., Martin F., and Zamvil S.S. B cell activation influences T cell polarization and outcome of anti-CD20 B cell depletion in CNS autoimmunity *Ann Neurol*. 2010 Sep;68(3):369-83.
6. Lehmann-Horn K., Schleich E. Hertzenberg D., Hapfelmeier A., Kümpfel T., von Bubnoff N., Hohlfeld R., Berthele A., Hemmer B., **Weber M.S.** Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. *J Neuroinflammation.* 2011 Oct 26;8:146 5
7. Hertzenberg D., Lehmann-Horn K., Husterer V., Cravens P.D., Kieseier B.C., Hemmer B., Brück W., Zamvil S.S., Stüve O., **Weber M.S.** Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity; *Eur J Immunol*, 2013 Aug;43(8):2078-88.
8. Molnarfi N., Schulze-Topphoff U., **Weber M.S**., Patarroyo J.C., Prod'homme T., Varrin-Doyer M., Shetty A., Linington C., Slavin A.J., Hidalgo J., Jenne D.E., Wekerle H., Sobel R.A., Bernard C.C.A., Shlomchik M.J., Zamvil S.S. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies; *J Exp Med.*, 2013 Dec 16;210(13):2921-37. 13
9. Kinzel S., Lehmann-Horn K., Torke S., Häusler D., Feldmann L., Winkler A., Stadelmann C., Payne N., Saiz A., Reindl M., Bernard C.C., Lalive P.H., Brück W., **Weber M.S.** Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. *Acta Neuropathol. 2016 Jul;132(1):43-58*
10. Romanelli E., Merkler D., Mezydlo A., Weil M.T., **Weber M.S.,** Nikic I., Potz S., Meinl E. Matznick F., Kreutzfeldt M., Ghanem A., Conzelmann K.K., Metz I., Brück W., Routh M., Simons M., Bishop D., Misgeld T., Kerschensteiner M. Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model. *Nat Commun.* 2016 Nov 16;7:13275

Göttingen, March 5th, 2017